Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Medical Industry Today.
Press releases published on May 14, 2025
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th
GlobeNewswire
·
May 14, 2025
MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform …
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine
GlobeNewswire
·
May 14, 2025
Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s …
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
GlobeNewswire
·
May 14, 2025
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of …
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 14, 2025
MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results …
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in …
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
GlobeNewswire
·
May 14, 2025
BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial …
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 14, 2025
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results …
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 14, 2025
Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment …
Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025 met veelbelovende nieuwe resultaten uit de ATALANTA-1 studie met CAR-T kandidaat GLPG5101
GlobeNewswire
·
May 14, 2025
Mechelen, België; 14 mei 2025, 22:01 CET; Galapagos NV (Euronext …
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
GlobeNewswire
·
May 14, 2025
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext …
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
May 14, 2025
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort …
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 14, 2025
PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on May 9, 2025, the compensation committee …
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award
GlobeNewswire
·
May 14, 2025
LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner. The Top Workplaces program has an 18-year history of …
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
GlobeNewswire
·
May 14, 2025
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong Balance Sheet with $294.4 Million in Cash and Cash …
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
·
May 14, 2025
VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for …
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
GlobeNewswire
·
May 14, 2025
On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human …
Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 …
Physician Reveals Concerning Trend in Health Care Pricing and What Can Be Done About It
EIN Presswire
·
May 14, 2025
TX, UNITED STATES, May 14, 2025 /EINPresswire.com/ -- Surveys show most doctors are increasingly concerned about a trend in health care pricing; patients being charged more for the same service, depending on where they go. And most don’t even know it’s …
Fluoroscopy Market Set for Growth Driven by Rising Chronic Diseases, Aging Population, and Demand
EIN Presswire
·
May 14, 2025
Increasing prevalence of chronic diseases, rising demand for minimally invasive procedures, and advancements in fluoroscopy technologies. VANCOUVER, BRITISH COLUMBIA, CANADA, May 14, 2025 /EINPresswire.com/ -- The Fluoroscopy Market is expected to grow …
Global Deeptech Conference at OIST in Okinawa, Japan Opens Startup Pitch Applications for Entrepreneurs
EIN Presswire
·
May 14, 2025
Unlocking Japan’s Deep Tech Startup Frontier—Apply Now to Pitch Your Startup on a Global Stage ONNA VILLAGE, OKINAWA, JAPAN, May 14, 2025 /EINPresswire.com/ -- Lifetime Ventures proudly announces OIST-Lifetime Startup Elevate 2025 (Startup Elevate 2025 …